Design Therapeutics is a clinical-stage company developing small-molecule drugs that turn disease genes up or down, led by DT-216P2 for Friedreich ataxia; none is approved.
Design's case rests on DT-216P2, a weekly IV small molecule designed to restore frataxin, the protein people with Friedreich ataxia lack. At 1 mg/kg it raised blood frataxin protein 22-27% over four weeks in RESTORE-FA, without a placebo group, and three patients also on Skyclarys had temporary liver enzyme rises. Design expects 12-week data in Q1 2027, and in March said its cash would fund operations into 2029.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: 12-week RESTORE-FA data show larger frataxin gains
Does 12 weeks of DT-216P2 at 1 mg/kg raise frataxin protein enough to support a registrational trial?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Design's DT-216P2 raised frataxin and improved ataxia scores over four weeks in 16 Friedreich ataxia patients; 12-week data moved to Q1 2027, with a registrational plan due in Q4 2026
DT-216P2's Phase 1/2 mFARS and frataxin biomarker data in FA sets up a registrational bet contingent on FDA accepting a small-molecule epigenetic approach as approvable
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Eye diseases, Neuromuscular diseases, Neurology and pain
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
12 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.